肢端肥大症药物治疗进展

doi:10.16138/j.1673-6087.2023.04.017

摘要/Abstract

中图分类号:

R584

郑思畅, 周薇薇, 王卫庆. 肢端肥大症药物治疗进展[J]. 内科理论与实践, 2023, 18(04): 292-296.

ZHENG Sichang, ZHOU Weiwei, WANG Weiqing. Therapy progress for acromegaly[J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(04): 292-296.

图/表 1

参考文献 56

[1]	Colao A, Grasso LFS, Giustina A, et al. Acromegaly[J]. Nat Rev Dis Primers, 2019, 5(1): 20. doi: 10.1038/s41572-019-0071-6 pmid: 30899019
[2]	Melmed S, Bronstein MD, Chanson P, et al. A Consensus Statement on acromegaly therapeutic outcomes[J]. Nat Rev Endocrinol, 2018, 14(9): 552-561. doi: 10.1038/s41574-018-0058-5 pmid: 30050156
[3]	中华医学会内分泌学分会. 肢端肥大症诊治中国专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36(9): 751-760.
[4]	Brooks AJ, Waters MJ. The growth hormone receptor: mechanism of activation and clinical implications[J]. Nat Rev Endocrinol, 2010, 6(9): 515-525. doi: 10.1038/nrendo.2010.123 pmid: 20664532
[5]	Tritos NA, Miller KK. Diagnosis and management of pituitary adenomas[J]. JAMA, 2023, 329(16): 1386-1398. doi: 10.1001/jama.2023.5444 URL
[6]	Geer EB. Medical therapy for refractory pituitary adenomas[J]. Pituitary, 2023, 26(3): 303-306. doi: 10.1007/s11102-023-01320-9
[7]	Giustina A, Mazziotti G, Torri V, et al. Meta-analysis on the effects of octreotide on tumor mass in acromegaly[J]. PLoS One, 2012, 7(5): e36411. doi: 10.1371/journal.pone.0036411 URL
[8]	Carmichael JD, Bonert VS, Nuño M, et al. Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments[J]. J Clin Endocrinol Metab, 2014, 99(5): 1825-1833. doi: 10.1210/jc.2013-3757 pmid: 24606084
[9]	Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study[J]. J Clin Endocrinol Metab, 2014, 99(3): 791-799. doi: 10.1210/jc.2013-2480 pmid: 24423324
[10]	Melmed S, Popovic V, Bidlingmaier M, et al. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase Ⅲ trial[J]. J Clin Endocrinol Metab, 2015, 100(4): 1699-1708. doi: 10.1210/jc.2014-4113 URL
[11]	Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice[J]. Front Neuroendocrinol, 2013, 34(3): 228-252. doi: 10.1016/j.yfrne.2013.07.005 URL
[12]	Schmid HA, Brue T, Colao A, et al. Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly[J]. Endocrine, 2016, 53(1): 210-219. doi: 10.1007/s12020-016-0895-8 pmid: 26906713
[13]	Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis[J]. J Clin Endocrinol Metab, 2011, 96(5): 1327-1335. doi: 10.1210/jc.2010-2443 pmid: 21325455
[14]	Kuhn E, Chanson P. Cabergoline in acromegaly[J]. Pituitary. 2017, 20(1): 121-128. doi: 10.1007/s11102-016-0782-6 pmid: 28025719
[15]	Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs[J]. JAMA Intern Med, 2014, 174(12): 1930-1933. doi: 10.1001/jamainternmed.2014.5262 pmid: 25329919
[16]	Kopchick JJ, Parkinson C, Stevens EC, et al. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly[J]. Endocr Rev, 2002, 23(5): 623-646. doi: 10.1210/er.2001-0022 pmid: 12372843
[17]	van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist[J]. Lancet, 2001, 358(9295): 1754-1759. doi: 10.1016/s0140-6736(01)06844-1 pmid: 11734231
[18]	Freda PU, Gordon MB, Kelepouris N, et al. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY[J]. Endocr Pract, 2015, 21(3): 264-274. doi: 10.4158/EP14330.OR pmid: 25370326
[19]	Tritos NA, Biller BM. Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly[J]. Pituitary, 2017, 20(1): 129-135. doi: 10.1007/s11102-016-0753-y pmid: 27631335
[20]	Fleseriu M, Führer-Sakel D, van der Lely AJ, et al. More than a decade of real-world experience of pegvisomant for acromegaly[J]. Eur J Endocrinol, 2021, 185(4): 525-538. doi: 10.1530/EJE-21-0239 pmid: 34342594
[21]	Bengtsson D, Schrøder HD, Andersen M, et al. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide[J]. J Clin Endocrinol Metab, 2015, 100(4): 1689-1698. doi: 10.1210/jc.2014-4350 pmid: 25646794
[22]	Burman P, Trouillas J, Losa M, et al. Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients[J]. Eur J Endocrinol, 2022, 187(4): 593-605. doi: 10.1530/EJE-22-0440 pmid: 36018781
[23]	Raverot G, Burman P, McCormack A, et al. European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas[J]. Eur J Endocrinol, 2018, 178(1): G1-G24. doi: 10.1530/EJE-17-0796 URL
[24]	中国垂体腺瘤协作组. 中国肢端肥大症诊治共识(2021版)[J]. 中华医学杂志, 2021, 101(27): 2115-2126.
[25]	Majd N, Waguespack SG, Janku F, et al. Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase Ⅱ study[J]. J Immunother Cancer, 2020, 8(2): e001532. doi: 10.1136/jitc-2020-001532 URL
[26]	Ilie MD, Villa C, Cuny T, et al. Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study[J]. Eur J Endocrinol, 2022, 187(5): 685-696. doi: 10.1530/EJE-22-0647 pmid: 36111659
[27]	Gatto F, Feelders RA, van der Pas R, et al. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly[J]. J Clin Endocrinol Metab, 2013, 98(1): E66-E71. doi: 10.1210/jc.2012-2609 URL
[28]	Wildemberg LE, Neto LV, Costa DF, et al. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs[J]. J Endocrinol Invest, 2013, 36(1): 38-43. doi: 10.3275/8305 pmid: 22472799
[29]	Iacovazzo D, Carlsen E, Lugli F, et al. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study[J]. Eur J Endocrinol, 2016, 174(2): 241-250. doi: 10.1530/EJE-15-0832 pmid: 26586796
[30]	Chiloiro S, Giampietro A, Mirra F, et al. Pegvisomant and pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response[J]. Eur J Endocrinol, 2021, 184(2): 217-229. doi: 10.1530/EJE-20-0767 pmid: 33136550
[31]	Muhammad A, Coopmans EC, Gatto F, et al. Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression[J]. J Clin Endocrinol Metab, 2019, 104(3): 915-924. doi: 10.1210/jc.2018-01524 pmid: 30346538
[32]	Venegas-Moreno E, Flores-Martinez A, Dios E, et al. E-cadherin expression is associated with somatostatin analogue response in acromegaly[J]. Cell Mol Med, 2019, 23(5): 3088-3096. doi: 10.1111/jcmm.2019.23.issue-5 URL
[33]	Puig-Domingo M, Gil J, Sampedro-Nuñez M, et al. Molecular profiling for acromegaly treatment: a validation study[J]. Endocr Relat Cancer, 2020, 27(6): 375-389. doi: 10.1530/ERC-18-0565 URL
[34]	Fusco A, Zatelli MC, Bianchi A, et al. Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas[J]. J Clin Endocrinol Metab, 2008, 93(7): 2746-2750. doi: 10.1210/jc.2008-0126 URL
[35]	Kasuki L, Wildemberg LE, Neto LV, et al. Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern[J]. Eur J Endocrinol, 2013, 169(2): 217-223. doi: 10.1530/EJE-13-0349 pmid: 23749849
[36]	Quabbe HJ, Plöckinger U. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly[J]. J Clin Endocrinol Metab, 1989, 68(5): 873-881. doi: 10.1210/jcem-68-5-873 URL
[37]	Colao A, Ferone D, Lastoria S, et al. Prediction of efficacy of octreotide therapy in patients with acromegaly[J]. J Clin Endocrinol Metab, 1996, 81(6): 2356-2362.
[38]	Biermasz NR, Pereira AM, Smit JW, et al. Intravenous octreotide test predicts the long term outcome of treatment with octreotide-long-acting repeatable in active acromegaly[J]. Growth Horm IGF Res, 2005, 15(3): 200-206. pmid: 15935982
[39]	Gilbert JA, Miell JP, Chambers SM, et al. The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly[J]. Clin Endocrinol (Oxf), 2005, 62(6): 742-747. doi: 10.1111/cen.2005.62.issue-6 URL
[40]	Karavitaki N, Botusan I, Radian S, et al. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly[J]. Clin Endocrinol (Oxf), 2005, 62(3): 282-288. doi: 10.1111/cen.2005.62.issue-3 URL
[41]	de Herder WW, Taal HR, Uitterlinden P, et al. Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly[J]. Eur J Endocrinol, 2005, 153(1): 67-71. pmid: 15994747
[42]	Pokrajac A, Claridge AG, Shakoor SK, et al. The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly[J]. Eur J Endocrinol, 2006, 154(2): 267-274. pmid: 16452540
[43]	Carlsen SM, Svartberg J, Schreiner T, et al. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure[J]. Clin Endocrinol (Oxf), 2011, 74(6): 736-743. doi: 10.1111/cen.2011.74.issue-6 URL
[44]	Wang M, Shen M, He W, et al. The value of an acute octreotide suppression test in predicting short-term efficacy of somatostatin analogues in acromegaly[J]. Endocr J, 2016, 63(9): 819-834. doi: 10.1507/endocrj.EJ16-0175 pmid: 27432816
[45]	Bandgar TR, Sarathi V, Shivane V, et al. The value of an acute octreotide suppression test in predicting response to long-term somatostatin analogue therapy in patients with acromegaly[J]. J Postograd Med, 2010, 56(1): 7-11.
[46]	Ershadinia N, Tritos NA. Diagnosis and treatment of acromegaly[J]. Mayo Clin Proc, 2022, 97(2): 333-346. doi: 10.1016/j.mayocp.2021.11.007 pmid: 35120696
[47]	Nunes VS, Correa JM, Puga ME, et al. Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system[J]. Pituitary, 2015, 18(4): 500-508. doi: 10.1007/s11102-014-0602-9 pmid: 25261979
[48]	Papaioannou C, Druce M. Preoperative medical treatments and surgical approaches for acromegaly[J]. Clin Endocrinol (Oxf), 2023, 98(1): 14-31. doi: 10.1111/cen.v98.1 URL
[49]	Puig-Domingo M, Soto A, Venegas E, et al. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice[J]. Endocrinol Nutr, 2016, 63(8): 397-408. doi: 10.1016/j.endonu.2016.05.010 pmid: 27448708
[50]	Lim DS, Fleseriu M. The role of combination medical therapy in the treatment of acromegaly[J]. Pituitary, 2017, 20(1): 136-148. doi: 10.1007/s11102-016-0737-y pmid: 27522663
[51]	Vilar L, Azevedo MF, Naves LA, et al. Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR[J]. Pituitary, 2011, 14(2): 148-156. doi: 10.1007/s11102-010-0272-1 pmid: 21104199
[52]	Suda K, Inoshita N, Iguchi G, et al. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature[J]. Endocr J, 2013, 60(4): 507-515. pmid: 23291436
[53]	Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly[J]. Lancet, 2005, 365(9471): 1644-1646. doi: 10.1016/S0140-6736(05)63011-5 pmid: 15885297
[54]	Strasburger CJ, Mattsson A, Wilton P, et al. Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant[J]. Eur J Endocrinol, 2018, 178(4): 321-329. doi: 10.1530/EJE-17-0996 pmid: 29371335
[55]	Higham CE, Atkinson AB, Aylwin S, et al. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial[J]. J Clin Endocrinol Metab, 2012, 97(4): 1187-1193. doi: 10.1210/jc.2011-2603 pmid: 22278424
[56]	Bernabeu I, Alvarez-Escolá C, Paniagua AE, et al. Pegvisomant and cabergoline combination therapy in acromegaly[J]. Pituitary, 2013, 16(1): 101-108. doi: 10.1007/s11102-012-0382-z pmid: 22396133

研究	药物剂量	病例数（n）	抑制切点	治疗目标	预测价值	结论
Karavitaki等^[40]，2005	100 μg s.c. 6 h	30	Nadir GH<5.25 mU/L	GH<5 mU/L	PPV 94%，NPV 100%	推荐
Biermasz等^[38]，2005	50 μg i.v. 3 h	18	Nadir GH<5 mU/L	GH<5 mU/L IGF-1正常	PPV 73%，NPV 57%	推荐
Gilbert等^[39]，2005	50 μg s.c. 6 h	33	Nadir GH<5 mU/L	GH<5 mU/L	灵敏度80%，特异度83%	推荐
Bandgar等^[45]，2010	50 μg s.c. 6 h	10	Nadir GH<1 μg/L	Nadir GH<1 μg/L IGF-1正常	PPV 100%，NPV 83%	推荐
Wang等^[44]，2016	100 μg s.c. 6 h	67	GH降低86.63%； GH降低90.51%	GH<2.5 μg/L或降低75%；肿瘤缩小	灵敏度93.8% 特异度85.7%；灵敏度84.8% 特异度87.5%	推荐
Colao等^[37]，1996	100 μg s.c. 6 h	68	mGH降低50%	GH<5 μg/L	PPV 43%，NPV 78%	不推荐
de Herder等^[41]，2005	50 μg s.c. 8 h	24	mGH降低50%； mGH降低75%； Nadir GH<1.1 μg/L； Nadir GH<2 μg/L；	IGF-1正常	PPV 58%，NPV 100%； PPV 73%，NPV 77%； PPV 65%，NPV 69%； PPV 82%，NPV 46%	不推荐
Pokrajac等^[42]，2006	50/100 μg s.c. 9 h	42	Nadir GH<5 mU/L； GH降低75%	GH<5 mU/L IGF-1正常	PPV 82%，NPV 50%； PPV 72%，NPV 40%	不推荐
Carlsen等^[43]，2011	50 μg s.c. 4 h	31	GH降低50%	GH<2 mU/L IGF-1正常	可预测GH降低，无法预测肿瘤缩小	不推荐

肢端肥大症药物治疗进展

Therapy progress for acromegaly

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 56

相关文章 13

编辑推荐

Metrics

本文评价

[1]	何佳佳，龚智标，张建宁，朱涛. 医用胶原-羟基磷灰石人工骨用于鞍底重建的临床研究[J]. 组织工程与重建外科杂志, 2017, 13(1): 21-24.
[2]	迟婧, 宋琦, 岳婧婧, 丁蓓, 黄娟, 凌华威, 方文强, 陈克敏, 严福华,. MRI对垂体柄阻断综合征的诊断价值[J]. 诊断学理论与实践, 2014, 13(05): 487-490.
[3]	高学金, 王新颖,. 营养不良与生长激素抵抗的研究进展[J]. 外科理论与实践, 2014, 19(01): 71-74.
[4]	朱晨芳, 孙波, 钟强, 顾岩,. 重组人生长激素对裸鼠肝癌移植瘤生长转移的实验研究[J]. 外科理论与实践, 2011, 16(02): 176-180.
[5]	吴晓宇, 刘福坤, 姚学权, 李为苏, 许哲, 陈彻,. 重组人生长激素减少人结肠癌细胞株放疗诱导的细胞凋亡[J]. 外科理论与实践, 2009, 14(04): 411-414.
[6]	刘广鹏，崔磊，曹谊林. 软骨生长板基因调控机制的研究进展[J]. 组织工程与重建外科杂志, 2006, 2(2): 110-112.
[7]	蒿汉坤, 陈宗祐, 蔡端, 华鲁纯, 龚佳蕾, 张延龄,. 生长抑素抑制人结肠癌细胞增殖的实验研究[J]. 外科理论与实践, 2006, 11(05): 421-424.
[8]	于健春. 生长激素、营养支持与恶性肿瘤[J]. 外科理论与实践, 2004, 9(05): 364-366+372.
[9]	刘敦贵,蒋继贫,魏来. 谷氨酰胺和生长激素在危重器官移植病人中的应用[J]. 外科理论与实践, 2004, 9(05): 390-392.
[10]	吴华成,李晔,许海敏,叶挺军. 垂体腺瘤100例临床病理分析[J]. 诊断学理论与实践, 2003, 2(02): 33-36.
[11]	殷保兵,马保金,蔡端,张延龄. 生长抑素和生长激素联合治疗术后胃肠吻合口出血的临床疗效观察(附36例报告)[J]. 外科理论与实践, 2002, 7(03): 235-236.
[12]	何桂珍,杨乃发,刘跃武,舒红,李德敏. 谷氨酰胺和生长激素联合应用对大鼠氨基酸水平的影响[J]. 外科理论与实践, 2002, 7(01): 69-70.
[13]	吴肇汉. 肠内、外营养在良性疾病中的应用[J]. 外科理论与实践, 1998, 3(01): 31-5.